Therapeutic Inertia

TKG PACT Executive Briefings - 3-Minute Market Insights

内容由The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri提供。所有播客内容（包括剧集、图形和播客描述）均由 The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

23d ago 3:25

MP3•单集首页

Send us a Text Message.

The term therapeutic inertia describes the failure of health care providers to initiate or intensify therapy when it is clearly indicated by established guidelines. The term has largely been applied to the management of blood pressure, blood sugar, and cholesterol, by primary care physicians who recognize the need for their patients to control these conditions but fail to act sufficiently to achieve the guideline recommended therapeutic targets. Despite clearly articulated, evidence-based, clinical guidelines, some physicians fail to translate this knowledge into practice. We believe that therapeutic inertia plays a significant role in delaying the adoption of many new treatments.

Most practitioners function within a “personal comfort zone” of prescribing behavior, being reluctant to take unnecessary risks with new drugs. There is a natural “learning curve,” where clinicians need to learn the side effect profiles and characteristics of new drugs, as well as to be assured that the drugs perform as promised.

You may download the full TKG PACT Executive Briefing highlighted in this episode, at Executive Briefings | TKG PACT

We welcome your suggestions, ideas, and requests for Executive Briefing topics of interest. Please email us at Insights@thekinetixgroup.com.

49集单集